全文获取类型
收费全文 | 50320篇 |
免费 | 3978篇 |
国内免费 | 112篇 |
专业分类
耳鼻咽喉 | 475篇 |
儿科学 | 1882篇 |
妇产科学 | 1329篇 |
基础医学 | 6240篇 |
口腔科学 | 461篇 |
临床医学 | 6409篇 |
内科学 | 9118篇 |
皮肤病学 | 1027篇 |
神经病学 | 5113篇 |
特种医学 | 1003篇 |
外国民族医学 | 1篇 |
外科学 | 5282篇 |
综合类 | 438篇 |
现状与发展 | 1篇 |
一般理论 | 86篇 |
预防医学 | 7107篇 |
眼科学 | 904篇 |
药学 | 3524篇 |
中国医学 | 80篇 |
肿瘤学 | 3930篇 |
出版年
2024年 | 52篇 |
2023年 | 487篇 |
2022年 | 817篇 |
2021年 | 1856篇 |
2020年 | 1133篇 |
2019年 | 1829篇 |
2018年 | 1920篇 |
2017年 | 1482篇 |
2016年 | 1580篇 |
2015年 | 1657篇 |
2014年 | 2339篇 |
2013年 | 3072篇 |
2012年 | 4553篇 |
2011年 | 4470篇 |
2010年 | 2445篇 |
2009年 | 2024篇 |
2008年 | 3499篇 |
2007年 | 3454篇 |
2006年 | 3206篇 |
2005年 | 3005篇 |
2004年 | 2595篇 |
2003年 | 2185篇 |
2002年 | 1891篇 |
2001年 | 231篇 |
2000年 | 170篇 |
1999年 | 242篇 |
1998年 | 317篇 |
1997年 | 228篇 |
1996年 | 185篇 |
1995年 | 165篇 |
1994年 | 120篇 |
1993年 | 107篇 |
1992年 | 89篇 |
1991年 | 64篇 |
1990年 | 76篇 |
1989年 | 83篇 |
1988年 | 62篇 |
1987年 | 48篇 |
1986年 | 51篇 |
1985年 | 63篇 |
1984年 | 64篇 |
1983年 | 49篇 |
1982年 | 29篇 |
1981年 | 33篇 |
1980年 | 35篇 |
1979年 | 33篇 |
1978年 | 38篇 |
1976年 | 29篇 |
1973年 | 33篇 |
1972年 | 26篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
993.
Krieger Penina Melmed Kara R. Torres Jose Zhao Amanda Croll Leah Irvine Hannah Lord Aaron Ishida Koto Frontera Jennifer Lewis Ariane 《Journal of thrombosis and thrombolysis》2022,54(2):350-359
Journal of Thrombosis and Thrombolysis - In patients who undergo thrombectomy for acute ischemic stroke, the relationship between pre-admission antithrombotic (anticoagulation or antiplatelet) use... 相似文献
994.
Vestal Mark L. Hodulik Kimberly Mando-Vandrick Jennifer James Michael L. Ortel Thomas L. Fuller Matthew Notini Maria Friedland Mark Welsby Ian J. 《Journal of thrombosis and thrombolysis》2022,53(1):167-175
Journal of Thrombosis and Thrombolysis - Limited data exists regarding the clinical outcomes of andexanet alfa and four factor prothrombin complex concentrate (4F-PCC) for reversal of apixaban or... 相似文献
995.
Piers Blombery Lucy C. Fox Georgina L. Ryland Ella R. Thompson Jennifer Lickiss Michelle McBean Satwica Yerneni David Hughes Anthea Greenway Francoise Mechinaud Erica M. Wood Graham J. Lieschke Jeff Szer Pasquale Barbaro John Roy Joel Wight Elly Lynch Melissa Martyn Clara Gaff David Ritchie 《Haematologica》2021,106(1):64
Bone marrow failure (BMF) related to hypoplasia of hematopoietic elements in the bone marrow is a heterogeneous clinical entity with a broad differential diagnosis including both inherited and acquired causes. Accurate diagnostic categorization is critical to optimal patient care and detection of genomic variants in these patients may provide this important diagnostic and prognostic information. We performed real-time, accredited (ISO15189) comprehensive genomic characterization including targeted sequencing and whole exome sequencing in 115 patients with BMF syndromes (median age 24 years, range: 3 months - 81 years). In patients with clinical diagnoses of inherited BMF syndromes, acquired BMF syndromes or clinically unclassifiable BMF we detected variants in 52% (12 of 23), 53% (25 of 47) and 56% (25 of 45) respectively. Genomic characterization resulted in a change of diagnosis in 30 of 115 (26%) including the identification of germline causes for 3 of 47 and 16 of 45 cases with pre-test diagnoses of acquired and clinically unclassifiable BMF respectively. The observed clinical impact of accurate diagnostic categorization included choice to perform allogeneic stem cell transplantation, disease-specific targeted treatments, identification of at-risk family members and influence of sibling allogeneic stem cell donor choice. Multiple novel pathogenic variants and copy number changes were identified in our cohort including in TERT, FANCA, RPS7 and SAMD9. Whole exome sequence analysis facilitated the identification of variants in two genes not typically associated with a primary clinical manifestation of BMF but also demonstrated reduced sensitivity for detecting low level acquired variants. In conclusion, genomic characterization can improve diagnostic categorization of patients presenting with hypoplastic BMF syndromes and should be routinely performed in this group of patients. 相似文献
996.
997.
Jennifer M. Logue Elisa Zucchetti Christina A. Bachmeier Gabriel S. Krivenko Victoria Larson Daniel Ninh Giovanni Grillo Biwei Cao Jongphil Kim Julio C. Chavez Aliyah Baluch Farhad Khimani Aleksandr Lazaryan Taiga Nishihori Hien D. Liu Javier Pinilla-Ibarz Bijal D. Shah Rawan Faramand Anna E. Coghill Marco L. Davila Bhagirathbhai R. Dholaria Michael D. Jain Frederick L. Locke 《Haematologica》2021,106(4):978
CD19 chimeric antigen receptor T (CAR T)-cell therapy with axicabtagene ciloleucel (axi-cel) for relapsed or refractory (R/R) large B-cell lymphoma (LBCL) may lead to durable remissions, however, prolonged cytopenias and infections may occur. In this single center retrospective study of 85 patients, we characterized immune reconstitution and infections for patients remaining in remission after axi-cel for LBCL. Prolonged cytopenias (those occurring at or after day 30 following infusion) were common with ≥grade 3 neutropenia seen in 21 of 70 (30%) patients at day 30 and persisting in 3 of 31 (9.7%) patients at 1 year. B cells were undetectable in 30 of 34 (88.2%) patients at day 30, but were detected in 11 of 19 (57.9%) at 1 year. Median immunoglobulin G levels levels reached a nadir at day 180. By contrast, CD4 T cells decreased from baseline and were persistently low with a median CD4 count of 155 cells/mL at 1 year after axi-cel (n=19, range: 33– 269). In total, 23 of 85 (27.1%) patients received intravenous immunoglobulins after axi-cel, and 34 of 85 (40%) received granulocyte-colony stimulating factor. Infections in the first 30 days occurred in 31 of 85 (36.5%) patients, of which 11 of 85 (12.9%) required intravenous antibiotics or hospitalization (“severe”) and were associated with cytokine release syndrome, neurotoxicity, tocilizumab use, corticosteroid use, and bridging therapy on univariate analyses. After day 30, seven severe infections occurred, with no late deaths due to infection. Prolonged cytopenias are common following axi-cel therapy for LBCL and typically recover with time. Most patients experience profound and prolonged CD4 T-cell immunosuppression without severe infection. 相似文献
998.
999.
1000.
Eastin Jennifer Dey Dzifa Amissah-Arthur Maame-Boatemaa Chaudhuri Kaushik Jawad Ali 《Clinical rheumatology》2021,40(9):3439-3443
Clinical Rheumatology - A project aimed to develop and deliver a clinical training course in Accra, Ghana, to increase patient access to physicians trained in the diagnosis, treatment and... 相似文献